Trials / No Longer Available
No Longer AvailableNCT02084121
Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Talaris Therapeutics Inc. · Industry
- Sex
- Male
- Age
- 3 Years
- Healthy volunteers
- —
Summary
A subject was treated under compassionate use provisions under this study with facilitating cell therapy (FCRx) product manufactured using the CliniMACS (Miltenyi Biotec) device, rather than the Max Sep (Baxter) device.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Enriched Hematopoetic Stem Cell Infusion | Enriched Hematopoetic Stem Cell Infusion |
Timeline
- First posted
- 2014-03-11
- Last updated
- 2022-07-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02084121. Inclusion in this directory is not an endorsement.